IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States.
High growth potential with adequate balance sheet.
Share Price & News
How has IsoRay's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ISR's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ISR exceeded the US Biotechs industry which returned 26.3% over the past year.
Return vs Market: ISR exceeded the US Market which returned 6% over the past year.
Price Volatility Vs. Market
How volatile is IsoRay's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StIsoRay, Inc. (NYSEMKT:ISR) Insiders Increased Their Holdings
1 month ago | Simply Wall StDo Directors Own IsoRay, Inc. (NYSEMKT:ISR) Shares?
2 months ago | Simply Wall StIs IsoRay (NYSEMKT:ISR) In A Good Position To Invest In Growth?
Is IsoRay undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ISR's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ISR's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ISR is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: ISR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ISR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ISR is overvalued based on its PB Ratio (7.3x) compared to the US Biotechs industry average (3.6x).
How is IsoRay forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ISR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: ISR is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ISR's is expected to become profitable in the next 3 years.
Revenue vs Market: ISR's revenue (27.8% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: ISR's revenue (27.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ISR's Return on Equity is forecast to be high in 3 years time
How has IsoRay performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ISR is currently unprofitable.
Growing Profit Margin: ISR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ISR is unprofitable, and losses have increased over the past 5 years at a rate of -3.5% per year.
Accelerating Growth: Unable to compare ISR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ISR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: ISR has a negative Return on Equity (-57.63%), as it is currently unprofitable.
How is IsoRay's financial position?
Financial Position Analysis
Short Term Liabilities: ISR's short term assets ($5.7M) exceed its short term liabilities ($1.7M).
Long Term Liabilities: ISR's short term assets ($5.7M) exceed its long term liabilities ($1.4M).
Debt to Equity History and Analysis
Debt Level: ISR is debt free.
Reducing Debt: ISR has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ISR has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ISR has less than a year of cash runway if free cash flow continues to reduce at historical rates of 8.5% each year
What is IsoRay current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ISR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ISR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ISR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ISR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ISR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Lori Holmes-Woods (58yo)
Ms. Lori A. Holmes-Woods has been Chief Executive Officer since December 12, 2018 and its Director at IsoRay, Inc. since June 4, 2018 and served as its Interim Chief Executive Officer since June 4, 2018 un ...
CEO Compensation Analysis
Compensation vs Market: Lori's total compensation ($USD416.52K) is below average for companies of similar size in the US market ($USD609.39K).
Compensation vs Earnings: Lori's compensation has increased whilst the company is unprofitable.
|CEO & Director||2.08yrs||US$416.52k||0.80% $341.7k|
|Executive Vice President of Sales & Marketing||4.33yrs||US$326.83k||0.16% $66.1k|
|Chief Research & Development Officer||1.42yrs||US$309.71k||0.030% $12.6k|
|CFO & Co-Principal Financial Officer||1.58yrs||US$166.02k||no data|
|COO & VP of Human Resources||1yr||no data||0.0080% $3.4k|
|Controller||3yrs||no data||0.024% $10.1k|
|Senior Director of Operations & Corporate Secretary||no data||no data||0.034% $14.4k|
Experienced Management: ISR's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
|CEO & Director||2.08yrs||US$416.52k||0.80% $341.7k|
|Independent Chairman of the Board||2.08yrs||US$65.61k||0.033% $13.9k|
|Independent Director||6.5yrs||US$65.61k||0.16% $69.3k|
|Independent Director||4.5yrs||US$65.61k||0.067% $28.3k|
Experienced Board: ISR's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
IsoRay, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: IsoRay, Inc.
- Ticker: ISR
- Exchange: AMEX
- Founded: 1983
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$42.613m
- Shares outstanding: 67.65m
- Website: https://www.isoray.com
Number of Employees
- IsoRay, Inc.
- 350 Hills Street
- Suite 106
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ISR||AMEX (NYSE MKT LLC)||Yes||Common Stock||US||USD||Aug 2005|
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. The company was formerly known as Century Park Pictures Corporation and changed its name to IsoRay, Inc. in 2005. IsoRay, Inc. was founded in 1983 and is headquartered in Richland, Washington.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/09 00:11|
|End of Day Share Price||2020/07/08 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.